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Abstract Bacterial infections are a frequently occurring
and major complication in human healthcare, in particular
due to the rapid increase of antimicrobial resistance and the
emergence of pan-drug-resistant microbes. Current
anatomical and functional imaging modalities are insuffi-
ciently capable of distinguishing sites of bacterial infection
from sterile inflammation. Therefore, definitive diagnosis
of an infection can often only be obtained by tissue biopsy
and subsequent culture and, occasionally, a definite diag-
nosis even appears to be impossible. To accurately diag-
nose bacterial infections early, novel imaging modalities
are urgently needed. In this regard, bacteria-targeted
imaging is an attractive option due to its specificity. Here,
different bacteria-targeted imaging approaches are
reviewed, and their promising future perspectives are
discussed.
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Introduction
Bacterial infections are of major concern both in hospital
and community settings worldwide. Although much fun-
damental knowledge has been gained about micro-organ-
isms and antimicrobial therapy, infections remain
responsible for substantial patient morbidity and mortality
these days [1]. In addition, infections become increasingly
difficult to treat due to the rapid increase of antimicrobial
resistance and the spread of pan-drug-resistant microbes
[2, 3]. Besides the fact that drug-resistant infections are
difficult to treat, their associated healthcare costs are sub-
stantially higher. For example, 1–2 % of the total joint
arthroplasties will become infected, and the costs of
treating such infections can amount up to $107.000 per
case if caused by a resistant micro-organism. By compar-
ison, the costs of treating infections with antibiotic-sensi-
tive bacteria are substantially lower, revolving around
$68.000 [4].
Despite a vast array of new technologies for the detec-
tion and typing of pathogens [5], diagnosing infections is
often complex or even problematic. This results in a rela-
tively, or even completely, blind management of infec-
tions. This complexity is a consequence of the fact that
diagnosis is based on the combination of several non-
specific signs and symptoms, systemic inflammation
markers, and visualization with fairly unspecific imaging
techniques [6–8]. A definite diagnosis of infectious disease,
with evidence of infection and identification of the causa-
tive microbial species, can only be obtained by culture and/
or molecular detection. Ideally, this involves obtaining
material directly from the infective focus, which often
requires tissue biopsy for deep-seated infections. This
invasive diagnostic procedure takes many hours or even
several days to yield an answer and, occasionally, it is not
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even possible to obtain a representative biopsy. However,
infections can be treated better when diagnosed accurately
and early. Therefore, reliable and fast diagnostic processes
are desirable [9].
Current imaging modalities to diagnose infectious dis-
ease comprise anatomical imaging modalities, such as
computed tomography (CT), magnetic resonance imaging
(MRI), and ultrasound (US), as well as functional imaging
modalities, such as positron emission tomography (PET),
single-photon emission computed tomography (SPECT),
and scintigraphy. Unfortunately, these clinical imaging
modalities by themselves are unable to differentiate bac-
terial infection from other infections (i.e., viral, fungal or
parasitic), or from sterile inflammation [1, 10]. Ideally, an
imaging modality would allow for a reliable detection of
infection, differentiate infection from other causes of
inflammation, and thereby circumvent the need of more
invasive methods. Hence, a new imaging modality that
allows for sensitive and specific imaging of bacterial
infection, ideally even providing species and resistance
information to guide optimal therapy, would be of high
value in clinical practice. Such an imaging modality is
most likely to be found in bacteria-targeted imaging
approaches.
In this review, we present several bacteria-targeted
imaging approaches and promising future perspectives of
targeted imaging to diagnose infections.
Methods
A literature search was performed in PubMed, searching
for publications in English, in the period between January
1980 and February 2016. The following search terms and
variations thereof were used: imaging, detection, specific,
targeted, bacterial, radionuclide, optical and/or fluores-
cence. Of the publications thus retrieved, only those that
were aimed at bacteria-specific in vivo imaging, in animals
or humans, were selected. CT, MRI, and US were not
included, because in a separate search using the terms
computed tomography, magnetic resonance imaging, and
ultrasound, targeted, specific, bacterial, detection, articles
describing in vivo bacteria-specific imaging with CT, MRI
or US were identified. Only those tracers closest to clinical
introduction are reported.
Targeted imaging
In recent years, an increasing interest in targeted imaging
has been raised. Targeted imaging is based on an imaging
agent, such as a radionuclide or fluorophore, coupled to a
molecule (e.g., an antibody, an antibiotic, an antimicrobial
peptide, a metabolizable compound, a bacteriophage, or a
DNA/RNA-binding compound) that targets specific bac-
teria or other pathogens [9, 11]. Besides visualization of the
site of infection, targeted imaging might also allow for the
identification of the causative micro-organism. For addi-
tional information on the matter, we refer to the article of
Mills et al. in this edition [11]. A more extensive review on
targeted imaging was recently published by van Oosten
et al. [9].
Radionuclide imaging
The functional non-targeted imaging modalities PET with
18F-fluoro-deoxy-glucose (FDG) and leukocyte scintigra-
phy are nowadays frequently used to track down sites of
both infection and inflammation [12]. Imaging of infections
with 18F-FDG–PET remains challenging due to the fact
that all tissues with a high glucose uptake, such as brain,
heart, malignancies, sterile inflammation and physiological
wound healing, show increased FDG uptake [10]. Leuko-
cyte scintigraphy partly overcomes this drawback as it
allows to some extent the distinction between inflammation
and infection by comparing images at different acquisition
times [13]. However, a major drawback of leukocyte
scintigraphy is that it is very laborious, since it involves the
drawing of blood from the patient, harvesting and radio-
labeling of leukocytes, and re-administering of the labeled
leukocytes to the patient. Altogether, this procedure takes
several hours. Other non-targeted radionuclide imaging
techniques used to detect infections are 67Gallium-citrate
imaging and bone scintigraphy [10]. In addition, two-step
scintigraphy with streptavidin and 111Indium-biotin (111In-
biotin) has been described by several research groups
[14, 15]. The latter approach is based on the fact that
streptavidin binds 111In-biotin with high affinity. However,
this approach is unlikely to be bacteria-targeted as strep-
tavidin accumulates at sites of infection as well as sites of
inflammation [15].
The importance of non-invasive, specific, bacterial
imaging in real time has become widely recognized. Most
current knowledge on radionuclide-targeted imaging con-
cerns 99mTechnetium-ciprofloxacin (99mTc-ciprofloxacin;
Infecton). In this regard, a large multi-centre clinical trial
showed a sensitivity of 85.4 % and specificity of 81.7 %
for detecting bacterial infections with 99mTc-ciprofloxacin
[16]. Although the sensitivity seems promising, its speci-
ficity is relatively low. Several other studies showed similar
concern about the specificity of this imaging agent [17–19].
Indeed, 18F-labeled ciprofloxacin did not allow for bacte-
ria-specific imaging in humans [20]. PET scans in four
patients with bacterial soft tissue infections showed
increased uptake of the tracer in infected areas. However,
the signal was not retained in infected tissue and vanished
at similar elimination half-life as in healthy tissue. It was,
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therefore, suggested that the radioactive signal was related
to increased blood flow and vascular permeability in local
infection [20]. Furthermore, there is a disadvantage of
using ciprofloxacin due to the widespread resistance
against this antibiotic [21, 22]. Besides 99mTc-cipro-
floxacin, other antibiotic-based tracers used in patients are
radiolabeled ceftriaxone or fleroxacin [23, 24]. Indeed,
99mTechnetium-labeled ceftriaxone allowed for successful
visualization of infections in patients, but studies were too
small to draw a final conclusion about the sensitivity and
specificity of this tracer [23]. Also, many other antibiotics
have been radiolabeled and tested, mainly in animal
models [9].
As an alternative for labeled antibiotics, radiolabeled
synthetic fragments of the antimicrobial peptide ubiqui-
cidin can be used for detection of bacterial or fungal
infections in patients. Ubiquicidin is a peptide originally
isolated from mouse macrophages, and synthetic frag-
ments of ubiquicidin were shown to bind to both Gram-
positive and Gram-negative bacteria as well as to fungi.
Small clinical trials investigating radiolabeled ubiquicidin
showed a sensitivity of 100 % and a specificity from 80 to
100 % for detection of bacterial and fungal infections
[25–28]. Altogether, ten successful clinical studies have
been reported on specific imaging of infections with
radiolabeled ubiquicidin [29]. Importantly, 99mTc-
ubiquicidin allowed the detection of infections with
93.7 % accuracy and with a pooled data sensitivity and
specificity of 97.5 and 89 %, respectively. No immuno-
logical side effects were observed. Furthermore, a
radionuclide-mediated tracer based on the nucleoside
analog fialuridine [1-(2-deoxy-2-fluoro-b-D-arabino-fura-
nosyl)-5-iodouracil; FIAU] has been evaluated in patients.
It was shown that FIAU is taken up by bacteria and
incorporated into their DNA, while this was not the case
in human cells. Successful visualization of bacterial
infections using 124I-labeled FIAU has been reported,
with apparently no false-positive or false-negative results
in seven patients [30]. In contrast, a recent study inves-
tigating the use of 124I-FIAU to image prosthetic joint
infections in patients did not establish a clear correlation
between the infection status and imaging results [31].
Moreover, two clinical studies addressing the use of 124I-
FIAU were terminated because of poor image quality, and
a lack of correlation between FIAU uptake and bone
biopsy results (clinicaltrials.gov: NCT01705496 and
NCT01764919). Therefore, the future role of radiolabeled
FIAU in infection imaging is currently unclear.
Another extensively described approach, which is hardly
used anymore, is the imaging of infections with radiola-
beled human polyclonal immunoglobulin (HIG) [32–34].
HIG was supposed to accumulate at sites of infection, but it
is apparently not bacteria specific since the reported
specificity ranges from 50 to 90 %. This compromised
specificity is mainly due to the fact that inflammation often
results in a false-positive signal.
Not explored in humans so far, but promising as bac-
teria-specific imaging agents, are compounds that are
exclusively metabolized by bacteria. Recently, detection of
bacteria with the sugar 6-[18F]-fluoromaltose (18F-FM) has
been reported [35]. Maltose and maltodextrins appear to be
used as energy sources by the vast majority, if not all
bacteria, since they express the maltodextrin transport
complex in contrast to mammalian cells. 18F-FM, there-
fore, allows specific detection of all classes of bacteria and
distinction of bacterial infection from other causes of
inflammation. Another promising sugar for imaging pur-
poses is sorbitol, which is a sugar alcohol mainly metab-
olized by Gram-negative bacteria, especially
Enterobacteriaceae. 2-[18F]-fluoro-deoxy-sorbitol (18F-
FDS) was shown to allow for the specific detection of
infections with Escherichia coli or Klebsiella pneumoniae
in mice [36]. Importantly, 18F-FDS neither accumulated in
healthy nor malignant mammalian cells in vitro. Thus, 18F-
FM, 18F-FDS and other labeled compounds that can only
be metabolized by bacteria have a high potential for bac-
teria-targeted imaging and clinical translation.
Optical imaging
Use of optical (i.e., fluorescence) tracers for bacteria-tar-
geted imaging is an upcoming and interesting topic
nowadays. Optical imaging of infections seems highly
feasible and has some important advantages over
radionuclide imaging, such as (1) a high resolution, (2) the
absence of ionizing radiation and its associated risks, (3)
the possibility of real-time visualization, and (4) lower cost
[37–39]. An important drawback of optical imaging is its
limited penetration depth of maximally 1–2 cm using near
infrared tracers, and even less for tracers with shorter
wavelengths. This limited penetration depth makes fluo-
rescence imaging suitable mainly for imaging of surfaces
and superficially located structures, and thus solely appli-
cable in superficially located infections, such as soft tissue
or superficial implant infections, or in intra-operative
applications [40].
Over the past decades, much experience has been gained
in optical imaging, for example in the visualization of
tumors in image-guided surgery [41–43]. Indeed, tumor-
specific intra-operative fluorescence imaging of ovarian
cancer was shown feasible in 2011 by targeting the over-
expressed folate receptor-a in patients [44]. Especially
intra- and peri-operative fluorescence imaging is likely to
be of great value and major improvements, such as
enhanced visual information during surgery and, as a
consequence, improved sensitivity and specificity and more
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optimal resection margins, can be expected. In addition,
deeper signal penetration might be feasible with improve-
ments in fluorescence dyes and charge-coupled device
(CCD) cameras.
Despite the fact that many different fluorophores are
available, only a few fluorophores are approved and tested
for clinical use today, including fluorescein isothiocyanate
(FITC; emission maximum 518 nm), indocyanine green
(ICG; emission maximum 790 nm) and IRDye-800CW
(emission maximum 800 nm). To date, bacteria-targeted
fluorescence imaging is only described in a few in vivo
studies, but with very promising results. First, Ning et al.
showed specific uptake of fluorescently labeled maltodex-
trin by different bacterial strains and it was feasible to
distinguish bacterial infections from sterile inflammation
with high target-to-normal tissue (T/N) ratios in rats [45].
Second, Panizzi et al. used fluorescently and radiolabeled
inactivated prothrombin, which binds to the staphylococcal
coagulase produced by Staphylococcus aureus. These
authors were able to make a distinction between S. aureus-
induced versus Staphylococcus epidermidis-induced endo-
carditis, or sterile vegetations in mice [46]. Third, several
research groups described the use of a fluorescent bis zinc
(II)-dipicolylamine complex for infection imaging [47, 48].
This tracer attaches to the negatively charged membranes
of bacteria. Unfortunately, the specificity of the fluorescent
bis zinc (II)-dipicolylamine complex seems to be relatively
low since this tracer also binds to negatively charged
apoptotic cells [48]. Moreover, apoptotic cells are usually
phagocytosed by macrophages which may further reduce
the specificity. Lastly, non-invasive in vivo detection of
infection caused by the Gram-positive bacterium S. aureus
was shown using fluorescently labeled vancomycin [37].
Vancomycin-IRDye800CW (in short vanco-800CW)
allowed the detection of S. aureus infection in vivo through
several millimeters of tissue using a specialized CCD
camera (Fig. 1). This was shown not only in a mouse
model, but also in a human post-mortem model for bio-
material-associated infection. Vancomycin and IRDye-
800CW are both approved substances for use in clinical
practice, and it is therefore anticipated that vanco-800CW
may be introduced safely for clinical use in the near future
allowing for exploration of clinical applications. Whether
the actual clinical application of vanco-800CW could be
limited by increased vancomycin resistance in Gram-pos-
itive bacteria is currently unknown, but this is clearly a
potential drawback of all antibiotic-based tracers [9].
Optoacoustic imaging
The relatively new detection technology of optoacoustic
imaging has been recently suggested for use in clinical
imaging. Like optical imaging, this technique is based on
absorption of light of a certain wavelength by an appro-
priate fluorophore coupled to a specific targeting molecule.
After absorption of light, the fluorophore molecules will
undergo thermo-elastic expansion, which leads to the
emission of ultrasonic pressure waves. In optoacoustic
imaging, these ultrasonic waves are detected by specialized
sensors [49]. Optoacoustic imaging allows for deeper
visualization in tissue (around 11 cm in muscle tissue),
since ultrasonic waves have longer wavelengths and deeper
penetration than light [50]. This deeper penetration can
particularly be valuable in the visualization of, e.g., bac-
terial infection of biomaterials or endocarditis. Next to
these advantages, optoacoustic imaging offers a high res-
olution and high contrast comparable to that of MRI [49].
Other imaging modalities
Specific imaging with CT and MRI scanning has been
reported for imaging of malignancies, using targeted
modality-specific contrast agents [51, 52]. To the best of
our knowledge, examples of bacteria-targeted imaging with
CT or MRI in vivo have not yet been documented [9].
Neither were reports found addressing bacteria-specific
targeting in vivo with the gas-filled microbubbles that are
used as contrast agents in US [9]. Nevertheless, Anas-
tasiadis et al. showed feasibility of a combined optical and
acoustic evaluation in vitro, using targeted encapsulated
gas bubbles for detection of early- and late-stage biofilm
formation, potentially allowing for biofilm-specific imag-
ing with US in vivo [53].
Smart activatable tracers
An exciting approach in the field of infection-targeted
imaging is the detection of bacteria with the so-called
‘‘smart activatable tracers’’ (Fig. 2). Smart activat-
able tracers are optical tracers that are quenched in their
normal state, and thus do not emit any signal. When the
tracer encounters its target, the tracer is cleaved by bac-
terial enzymes, resulting in removal of the quencher.
Subsequently, a fluorescence signal is emitted that can be
detected. Imaging with smart activatable tracers usually
results in a higher T/N ratio as compared to conventional
tracers, and consequently in more efficient imaging.
Successful use of smart activatable tracers has been
reported for imaging tumors, as well as bacteria [54–56].
However, for infection imaging, results have so far only
been obtained in animal studies. Kong et al. designed a
smart activatable tracer based on a b-lactam ring, which is
hydrolyzed by bacterial b-lactamases, leading to activa-
tion of the fluorophore [55]. Successful imaging with this
tracer has been shown for Mycobacterium tuberculosis
infection in mice. Although only M. tuberculosis infection
256 Clin Transl Imaging (2016) 4:253–264
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imaging has been described, this tracer might be appli-
cable for all b-lactamase-producing bacteria. No T/N
ratios have been reported yet for this b-lactam smart
activatable tracer and, thus it is not clear whether the
smart activatable tracer in this case indeed offers the
increased T/N ratios required.
Furthermore, Hernandez et al. reported the non-inva-
sive detection of S. aureus infection in mice, with an
intravenously administered nuclease-activated tracer
[56]. The quenched fluorescence oligonucleotide tracer
is specifically activated by micrococcal nuclease (MN), a
nuclease secreted by S. aureus. This tracer was proven to
be MN- and thus S. aureus-specific, the mutated nucle-
ase-deficient S. aureus showed a significantly lower
signal. For this tracer, good T/N ratios have been
reported.
Fig. 1 In vivo optical imaging
of Staphylococcus aureus
infection. Micro-computed
tomography image of a mouse
that was infected with a
bioluminescent S. aureus strain
in the right hind limb, and with
a bioluminescent E. coli strain




emitted by the infecting S.
aureus and E. coli cells is
depicted in rainbow scale, and
the fluorescence signal due to
vanco-800CW-binding in red–
yellow scale. A clear co-
registration of bioluminescence
and NIR fluorescence was
detected at the site of S. aureus
infection. Moreover, a NIR
fluorescence signal was detected
in the bladder (in this image
visible behind the spine). This
bladder signal reflects the renal
excretion of the tracer.
Reprinted with permission from
[37]
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Multi-modality tracers
A combination of imaging modalities allows for the con-
current application of the advantageous properties of each
single modality, and thereby optimization of diagnosis.
Multi-modality tracers are based on a targeting molecule,
coupled to two or more imaging modality agents, such as
radionuclides, fluorophores, CT contrast agents, MRI
contrast agents, or microbubbles [57]. Such a multi-
modality tracer allows for imaging of a target with one
single tracer by two or more different imaging modalities
simultaneously. For example, this potentially offers an
opportunity for pre-operative detection of infection and
tracking down its localization and, subsequently, it offers a
possibility for optical visualization during invasive proce-
dures. Such multi-modality tracers have been described for
targeting inflammation (e.g., CD20 on B-cells, integrins
and matrix metalloproteinases) [58]. Notably, a bacteria-
targeted multi-modality tracer based on the antimicrobial
peptide ubiquicidin has recently been described [59].
Ubiquicidin was conjugated to a radioisotope and fluo-
rophore and this dual-modality tracer was able to detect S.
aureus and K. pneumoniae infections in vivo using a
combined imaging system. In our opinion, these multi-
modality tracers are potentially of great value in bacterial
infection imaging.
Photodynamic therapy
Besides using targeted modalities to optimize diagnosis of
infection, targeted therapy could be used to improve
infection treatment. In particular, targeted photodynamic
therapy (PDT) could play an important role in the treatment
of infections. PDT is based on excitation of photosensitive
molecules with light of a certain wavelength, resulting in
an optical signal as well as cytotoxic molecules that are
capable of destructing the targeted cells [60, 61]. Treatment
characteristics of this approach are promising, but
untargeted PDT leads to damage of healthy tissue due to
the non-specific uptake of photodynamic molecules, cur-
rently limiting this form of PDT to skin and dental infec-
tions [60, 62]. Targeted PDT might solve this drawback
and was already shown to be successful in cancer treatment
[61, 63]. It seems conceivable that targeted PDT could play
an important role in the treatment of bacterial infections as
well. Unfortunately, PDT would be limited to localized,
easily accessible or superficial infections due to a limited
penetration depth of available lasers. To date, there is little
experience with targeted PDT in infections in vivo. Raga`s
et al. showed eradication of methicillin-resistant S. aureus
(MRSA) infection in a murine burn wound model [64]. A
cationic photosensitizer, which was topically administered,
was used to target the bacteria. Although this technique
eradicated MRSA, it is questionable whether this tracer is
really ‘‘targeted’’, since the photosensitizer binds to the
negatively charged bacterial cell walls based on the
cationic molecules, which probably would also have
affinity for other negatively charged structures, such as
apoptotic tissue. There is some more experience with tar-
geted PDT in in vitro infection models. In this regard,
feasibility has been shown for antibody-directed and
antimicrobial peptides-directed PDT [65–67]. Suci et al.
described successful targeted PDT based on a biotinylated
photosensitizer and a biotinylated antibody specific for
Aggregatibacter actinomycetemcomitans, coupled by
streptavidin [68]. These results seem promising for the
treatment of periodontal biofilms. Overall, PDT seems to
be an interesting diagnostic and therapeutic application for
locoregional infections.
Potential clinical applications of targeted imaging
Targeted imaging could enable earlier detection of infec-
tions, resulting in earlier institution of an accurate treat-
ment. The more accurate treatment will subsequently
represent a crucial element in the fight against bacterial
Fig. 2 Mechanistic principle of
b-lactam-based smart-
activatable tracers. The intact
tracer does not emit light due to
the presence of a quencher (gray
sphere). After hydrolysis of the
b-lactam ring by a b-lactamase,
the quencher is detached from
the fluorophore (green sphere)
and the tracer emits light
258 Clin Transl Imaging (2016) 4:253–264
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resistance. Besides the application of targeted imaging in
pre-operative diagnostics and post-operative follow-up of
infections, it could also be used for intra-operative surgical
guidance, theoretically leading to a more optimal resection
of infected tissue and minimized damage in healthy tissue.
Potential use of tracers for different infections is out-
lined in Table 1.
Necrotizing fasciitis
Necrotizing fasciitis is a rapidly progressive infection of the
deeper layers of skin and subcutaneous tissues, which
requires immediate aggressive surgery and antibiotic ther-
apy. To date, surgeons mainly rely on visual and tactile
information during surgery. Infection borders of necrotizing
fasciitis are difficult to recognize and can only be analyzed
during surgery using frozen sections. Unfortunately, this is
an indirect method giving information only about the small
site of tissue where a biopsy was taken. Clearly, it is
desirable to develop new methods that provide the needed
information in real time and intra-operatively. Using tar-
geted imaging, surgeons can be provided with extra visual
information. In targeted optical imaging of ovarian cancer in
patients, surgeons were able to detect small tumor spots of
\1 mm [69]. Hypothetically, intra-operative targeted
imaging can also result in better detection of infection, and
more precise and radical resection, while sparing as much as
possible healthy tissue. This may eventually lead to a better
prognosis for patients with less mutilating outcomes. Pre-
sumably, targeted imaging would be of great value for
necrotizing fasciitis-related surgery in the future.
Septic arthritis
Septic arthritis is most commonly caused by bacteria, but
also fungi or viruses can be the causative agents. Notably,
also sterile inflammatory diseases, such as rheumatoid
arthritis or gout, are very common causes of arthritis.
Arthritis caused by bacterial pathogens is often rapidly
destructive, and thereby of the most fulminant subtype. In
daily practice, the causative agent of arthritis is difficult to
establish from the outside, and arthrocentesis is used to
collect synovial fluid. Subsequent microbiological cultur-
ing is needed to find evidence of infection and to identify
the responsible bacteria. Minimal-invasive targeted imag-
ing techniques would be of great importance in this clinical
Table 1 Overview of infections, with most common causative micro-organisms, and potentially suitable tracers for detection
Infection Common causative micro-organisms ([10 %) Potential tracers for detection Remarks
Necrotizing
fasciitis
Streptococcus pyogenes, other b-hemolytic
streptococci, Staphylococcus aureus; (an)aerobic
mixed flora, Clostridium perfringensa, other
clostridiaa
CEF, CIP, FIAU, MALT, UBI,
VAN
Septic arthritis Staphylococcus aureus, streptococci, N. gonorrhoeae CEF, CIP, FIAU, FLER, MALT,
NUC, PRO, UBI, VAN
Infective
endocarditis
S. aureus, coagulase negative staphylococci, viridans
streptococci, enterococci, HACEK organismsa




S. aureus, coagulase negative staphylococci,
streptococci, enterococci




S. aureus, coagulase negative staphylococci,
streptococci, enterococci
CEF, CIP, FIAU, MALT, NUC,
PRO, UBI, VAN
Meningitis Streptococcus pneumoniae, Neisseria meningitidis,
Haemophilus influenzae, Listeria monocytogenesa
CEF, FIAU, MALT, UBI The tracer has to cross the
blood–brain barrier
Bacteremia Miscellaneous CEF, CIP, FIAU, MALT, NUC,
PRO, SOR, UBI, VAN, BLA
Pneumonia Streptococcus pneumoniae, Haemophilus influenzae, S.
aureus. Hospital-acquired pneumonia: miscellaneous
CEF, CIP, FIAU, MALT, NUC,
PRO, SOR, UBI, BLA
Tracers can be suitable in two possible ways, namely (1) detection of infection by targeting the vast majority of causative pathogens, or (2) by
detection of particular species, which would have direct implications for the choice of therapy. Ideally, future approaches would offer both
possibilities. Potentially usable tracers not only include the tracers in their current published structures but also future variants (e.g., modification
from radiolabeled to optically labeled, or vice versa). Microorganisms and tracers are mentioned in alphabetical order
a Micro-organisms that occur in less than 10 % of the cases, but are classically associated with the respective infection. The specific tracers listed
are: 99mTc-ceftriaxone (CEF), 99mTc-ciprofloxacin/18F-ciprofloxacin (CIP), 124Iodine-FIAU (FIAU), 18F-fleroxacin (FLER), 6-[18F]-fluoromal-
tose/maltodextrin-based optical tracer (MALT), activatable nuclease-targeted optical tracer (S. aureus-directed; NUC), prothrombin-based
optical/radiolabeled tracer (PRO), 2-[18F]-fluoro-deoxy-sorbitol (SOR), 99mTc-ubiquicidin (UBI), vancomycin-IRDye 800CW (VAN), activat-
able b-lactamase-targeted optical tracer (BLA). HACEK organisms (fastidious Gram-negative bacilli): Haemophilus spp., Aggregatibacter
actinomycetemcomitans, Cardiobacterium hominis, Eikenella corrodens, Kingella kingae/Kingella denitrificans
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situation, to (1) quickly and adequately distinguish bacte-
rial arthritis from other pathologies, and (2) start early with
appropriate antibiotic therapy. This may lead to a better
prognosis for patients and a lowered chance of eliciting
bacterial resistance.
Infective endocarditis
Infective endocarditis (IE) causes serious morbidity and
mortality (40 % of all patients die in 1 year) [70]. There-
fore, early and accurate diagnosis is crucial. Unfortunately,
diagnosing IE remains a challenge in current clinical
practice, due to its variable clinical presentation of both
cardiac and extra-cardiac manifestations. Diagnosis of IE is
largely based on the modified Duke criteria, of which blood
cultures and echocardiography are cornerstones [71]. These
criteria have only a sensitivity and specificity of around
80 % when no artificial material is involved [71], and the
ultimate diagnosis has still to be made by expert clinical
judgement. Echocardiography has been shown to miss life-
threatening complications in 30 % of patients [72]. In
addition, blood cultures show no causative micro-organism
in up to 31 % of all cases of IE [73], partly due to prior
antimicrobial therapy. This poses considerable diagnostic
and therapeutic dilemmas in clinical practice, as anatomic
information guides indication and timing of surgical
treatment. Furthermore, it is essential to determine the
causative micro-organism and its resistance pattern to
implement appropriate antimicrobial therapy. Here,
opportunities for improved imaging are, obviously, highly
desirable. Promising results in this direction have been
published using conventional 18F-FDG–PET/CT and
leukocyte scintigraphy [74]. These functional techniques
use, respectively, 18F-FDG as tracer and PET/CT for
detection, or radiolabeled white blood cells (e.g., with
99mTc-HMPAO) as tracers and SPECT/CT for detection.
Pizzi et al. have reported the largest study to date evalu-
ating 18F-FDG–PET/CT in endocarditis. Their results show
that the largest group of 50 patients with possible endo-
carditis (54 %) could be reduced to 5 (5 %) [75]. Fur-
thermore, Rouzet et al. compared both imaging techniques
in IE, and their results mainly indicate that 18F-FDG–PET/
CT is more sensitive, whereas leukocyte scintigraphy is
more specific [76]. However, even when taking most recent
(non-specific) imaging developments into account [74],
more specific diagnosis of IE could prove critical in a vast
amount of remaining cases with diagnostic uncertainty. In
addition, opportunities to accelerate accurate diagnosis and
treatment could prove lifesaving. Therefore, targeted
imaging represents an appealing option for IE diagnosis.
For example, targeted imaging could disclose the patho-
genic bacterium in cases of negative blood cultures, so that
adequate antibiotic therapy can be given. Besides, targeted
imaging could point towards additional and distant sites of
cardiac infection, which should be taken into account in the
individualized therapy plan. On top of this, intra-operative
targeted imaging could visualize the exact borders of
infected tissue of which radical resection could potentially
improve patient outcome. This is likely to be highly
important in this condition since it is mandatory to
immediately implant prosthetic material in the area of
infected tissue.
Infected surgical meshes
Surgical meshes are commonly used to support tissue. In
particular, these meshes are useful for permanent support in
the repair of abdominal and inguinal hernias. Occasionally,
a wound infection will occur after surgical intervention
and, on longer term, intestinal-cutaneous fistulas can occur
after abdominal surgery. Often it is difficult to determine
whether and to what extent implanted meshes are involved
in these infectious processes. This is highly relevant to
predict prognosis and determine most optimal therapy.
Targeted imaging could provide information on (1) whe-
ther the mesh is involved in the infectious process, and (2)
what is the causing bacterial species. Due to the minimal-
invasive targeted imaging technique, a more invasive
technique, with ultimately preventive removal of the mesh,
may be avoided.
Infected vascular grafts
Superficial (i.e., dialysis shunts) and deeper seated (e.g.,
aortic aneurysm repair) vascular graft infections are
responsible for high patient morbidity and mortality, if not
treated immediately [77]. Frequently, only the outside of
the graft is infected resulting in negative blood cultures.
Nowadays, 18F-FDG–PET-scan and/or leukocyte scintig-
raphy are used for the diagnosis of vascular graft infections
in addition to the CT-scan. Both give information about
inflammatory activity, in addition to the anatomic infor-
mation derived from a simultaneous and/or separate CT-
scan. However, infection cannot be reliably distinguished
from sterile inflammation or physiological wound healing
using 18F-FDG–PET nor CT-scan. Therefore, early infec-
ted vascular grafts cannot always be readily detected [78].
Also, notwithstanding its high sensitivity (91 %), 18F-
FDG–PET is not an ideal imaging approach for detection
of infected vascular grafts since its specificity is rather low
(64 %) [77]. Leukocyte scintigraphy seems to allow for a
higher specificity, especially early post-operatively, and is
recommended if the CT-scan is inconclusive [79, 80].
Nevertheless, a non-invasive specific targeted imaging
technique is highly desirable for detection of infected
vascular grafts. The most important advantage of such a
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targeted approach is that an invasive surgical procedure is
not needed to diagnose bacterial infection, to determine
which vascular grafts are involved in infection, and to what
extent these grafts are affected. Targeted imaging that
allows for determination of the causative bacterial patho-
gen would highly aid in directing optimal therapy. This
would be especially helpful in detecting fastidious micro-
organisms that cannot be routinely cultured, such as Cox-
iella burnetii. Besides, intra-operative targeted imaging
could aid for determining the extent of infected tissue and
grafts, and for determining the most optimal resection
borders.
Meningitis
The diagnosis of meningitis is currently based on blood
tests (i.e., C-reactive protein and complete blood count),
blood cultures, and most importantly examination of the
cerebrospinal fluid (CSF). CSF should be obtained of every
patient with a suspicion of meningitis to identify the cau-
sative micro-organism unless a lumbar puncture is con-
traindicated (e.g., brain tumor, abscess, or a high
intracranial pressure). In selected patients a CT scan or
MRI scan is recommended prior to lumbar puncture to
check for the existence of contraindications, which delays
the actual puncture. As it is of great importance to treat
meningitis quickly with antibiotics, in these cases broad-
spectrum antimicrobial treatment is commonly initiated
before lumbar puncture to prevent treatment delay.
Unfortunately, this early start of antibiotic treatment often
interferes with finding the causative agent, whereas culture
of CSF that is obtained after start of antibiotic treatment
has a substantially lower sensitivity. A sensitive imaging
modality to detect meningitis at an early stage and to dis-
criminate between different causative pathogens would be
highly desirable [81]. Especially the new hybrid PET/MRI
approach seems very promising for distinguishing menin-
gitis from other pathologies such as abscesses and
encephalitis [82–84]. This might even allow a distinction of
meningitis caused by viruses from bacterial meningitis by
pattern recognition. Bacteria-targeted PET tracers, such as
18F-FDS or 18F-FM, which detect a subset or all bacterial
species, could more clearly distinguish bacterial infections
from other pathologies, and especially tracers that identify
particular bacterial groups or even species could enable
quick and more accurate treatment. An extra challenge
might be found in designing tracers that reliably pass the
blood–brain barrier upon intravenous administration. Also,
it remains to be seen whether the bacterial load in
meningitis is high enough for detection with the current
PET cameras, which have a relative low resolution
(3–4 mm). Clearly, a rapid and highly sensitive test for the
presence of bacteria using fluorescence tracers could
improve diagnostic accuracy and accelerate diagnosis in
patients where CSF has been obtained. This option could
make use of optical smart activatable tracers and dedicated
sensors which might be even used as bedside tests.
Bacteremia
The gold standard for diagnosis of bacteremia (in case of
sepsis or endocarditis) is the isolation of micro-organisms
from a blood culture. Ideally, blood cultures are obtained
prior to antimicrobial therapy. Unfortunately, it takes sev-
eral days of culture until the causative micro-organism with
its matching resistance pattern is identified. In case of
infection with a fastidious micro-organism or antibiotic
usage prior to the blood culture collection, identification of
the bacterial species can be problematic. Real-time detec-
tion of bacteria in the blood stream of a patient would,
therefore, be of great value. In particular, optical targeted
imaging might be ideal for this application, since this
makes real-time bedside measurements feasible. For
instance, the diagnosis of infection could potentially be
made much faster by implementing continuous measure-
ment systems. This could involve optical smart activat-
able tracers and dedicated sensors. Subsequently, this
would also allow for treatment follow-up, to detect whether
the bacterial load in the blood stream is decreasing.
Pneumonia
Currently, diagnosis of pneumonia comprises clinical
symptoms and signs, radiography and sputum culture.
Radiography reveals in most cases pulmonary infiltrates,
but differentiation between infection and other causes of
pulmonary infiltration (e.g., atelectasis, infarction, hemor-
rhage, acute respiratory distress syndrome and malignancy)
remains difficult with a specificity of only 33–70 %
[85, 86]. Sputum culture, or even more optimal broncho-
alveolar sample culture, can provide relevant information,
but it takes several days before a reliable identification of
the causative agent and its drug-resistance profile is
available, if at all. Besides, representative respiratory
material is often not obtainable due to the clinical situation
of the patient. As a consequence, physicians substantially
overtreat patients by early empirical initiation of broad-
spectrum antibiotic therapy. Thus, there is currently an
unmet need for fast and accurate diagnosis of pneumonia
and identification of its causative agent to allow narrow-
spectrum treatment and avoid unnecessary antibiotic usage.
Development of a set of infection-targeted optical tracers
for direct detection of pneumonia is a highly promising
approach. First clinical trials on bacteria-targeted imaging
are currently initiated at the Royal Infirmary in Edinburgh
to detect bacterial pneumonia using a bronchoscope
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combined with confocal laser endomicroscopy (clin
icaltrials.gov: NCT02558062 and NCT02491164). Poten-
tially, this approach can visualize pneumonia in situ, not
only providing direct cues about the presence and local-
ization of pneumonia, but also offering the possibility of
focused sample collection for subsequent microbiological
analysis (i.e., microscopy, culture or molecular analysis).
Conclusion
Bacteria-targeted imaging is of significant upcoming
interest. Progress has been made in the development of
specific tracers, as well as in the development of imaging
modalities to visualize infection. It remains difficult to
predict which tracers or modalities will prove most
appropriate for clinical use, but it is to be expected that
some of the approaches described in this review will
eventually find their place in routine clinical diagnostic
settings. The further implementation of new imaging
techniques, such as multi-modality imaging or optoacoustic
imaging, and smart activatable tracers, holds even greater
promise for quick and accurate detection of infections. This
may ultimately be extended to antibacterial therapy in case
of targeted PDT. We thus conclude that bacteria-targeted
imaging has a bright future.
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